The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•25 June 2026•

1 min read

ProQR Secures $50M from Eli Lilly After Positive Early Trial Data

Key Facts

1ProQR Therapeutics reported positive Phase 1 data for its drug AX-0810.

2The company raised $50 million in a share offering that included Eli Lilly.

In a move that underscores growing confidence in early-stage biotech, ProQR Therapeutics announced positive Phase 1 data for its drug AX-0810 and concurrently raised $50 million in a share offering that included Eli Lilly. The deal signals large pharma's appetite for promising early-stage assets.

Eli Lilly's investment in ProQR comes as big pharmaceutical companies increasingly seek to diversify their pipelines through strategic partnerships. The capital injection provides ProQR with a solid runway to advance its candidate targeting an undisclosed chronic disease.

Eli Lilly (LLY) shares closed at $1,117.26 on June 24, 2026, trading between $1,100.98 and $1,135.14 during the session. Investors now await further clinical updates for AX-0810 and any regulatory milestones that could affect the stock's trajectory.